Roivant Sciences Ltd.
Roivant Sciences Ltd.'s purchase track record
How the stock did after each of Roivant Sciences Ltd.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/12/2025 | IMVT | $350.00M | -7.6% | +27.3% | +8.8% |
| 1/13/2025 | IMVT | $336.90M | -32.2% | -18.3% | +7.4% |
| 10/2/2023 | IMVT | $58.00M | +19.5% | -8.8% | +22.3% |
| 10/6/2022 | IMVT | $2.50M | +90.9% | +47.3% | +9.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roivant Sciences receives downgrades from Wolfe Research and analyst. Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.
Transaction History
| ABUS | ▼ Sell | Other | 8,967,383 | $44.8M | 10/1/2026 | View on chart |
| ROIV | ▲ Buy | Open Market | 16,666,666 | $350.0M | 12/12/2025 | View on chart |
| ROIV | ▲ Buy | Open Market | 16,845,010 | $336.9M | 1/13/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 4,473,684 | $170.0M | 10/2/2023 | View on chart |
| ROIV | ▲ Buy | Open Market | 1,526,316 | $58.0M | 10/2/2023 | View on chart |
| ROIV | ▲ Buy | Open Market | 416,667 | $2.5M | 10/6/2022 | View on chart |
| ABUS | ▼ Sell | Other | 22,833,922 | — | 10/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
ABUS Featured in Whale Alert List of 10 Health Care Stocks
Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.
ABUS Featured in Whale Alert List of 10 Health Care Stocks. Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.